Abstract
Alzheimer’s disease (AD) represents the most prevalent form of dementia in the elderly. However, the pathological mechanisms underlying the development and progression of AD are only partially understood. To date, the accumulated clinical and experimental evidence indicate that the locus coeruleus (LC), the main source of brain’s norepinephrine, represents “the epicenter” of pathology leading to the development of AD. Evidence for this includes observations that neurons of the LC modulate several processes that are altered in brains of AD patients, including synaptic plasticity, neuroinflammation, neuronal metabolism, and blood-brain-barrier permeability. Moreover, the LC undergoes significant degeneration in the brains of AD patients and is considered a source of the prion-like spreading of tau pathology to forebrain structures innervated by the noradrenergic neurons of the LC. Furthermore, lesions of the LC exaggerate AD-related pathology, while augmentation of the brain’s noradrenergic neurotransmission reduces both neuroinflammation and cognitive decline. We hypothesize that better understanding the role of the LC neurons in AD pathogenesis may lead to development of new strategies for the treatment of AD.
Keywords: Alzheimer's disease, blood-brain-barrier, locus coeruleus, neuroinflammation, plasticity, tau protein.
Current Alzheimer Research
Title:Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Volume: 11 Issue: 10
Author(s): Boris Mravec, Katarina Lejavova and Veronika Cubinkova
Affiliation:
Keywords: Alzheimer's disease, blood-brain-barrier, locus coeruleus, neuroinflammation, plasticity, tau protein.
Abstract: Alzheimer’s disease (AD) represents the most prevalent form of dementia in the elderly. However, the pathological mechanisms underlying the development and progression of AD are only partially understood. To date, the accumulated clinical and experimental evidence indicate that the locus coeruleus (LC), the main source of brain’s norepinephrine, represents “the epicenter” of pathology leading to the development of AD. Evidence for this includes observations that neurons of the LC modulate several processes that are altered in brains of AD patients, including synaptic plasticity, neuroinflammation, neuronal metabolism, and blood-brain-barrier permeability. Moreover, the LC undergoes significant degeneration in the brains of AD patients and is considered a source of the prion-like spreading of tau pathology to forebrain structures innervated by the noradrenergic neurons of the LC. Furthermore, lesions of the LC exaggerate AD-related pathology, while augmentation of the brain’s noradrenergic neurotransmission reduces both neuroinflammation and cognitive decline. We hypothesize that better understanding the role of the LC neurons in AD pathogenesis may lead to development of new strategies for the treatment of AD.
Export Options
About this article
Cite this article as:
Mravec Boris, Lejavova Katarina and Cubinkova Veronika, Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107130505
DOI https://dx.doi.org/10.2174/1567205011666141107130505 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-HIV Drug Distribution to the Central Nervous System
Current Pharmaceutical Design Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Label-Free Cell Phenotypic Drug Discovery
Combinatorial Chemistry & High Throughput Screening Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Synthetic and Natural Coumarins as Antioxidants
Mini-Reviews in Medicinal Chemistry Biological Importance, Therapeutic Benefit and Analytical Aspects of Bioactive Flavonoid Pectolinarin in the Nature
Drug Metabolism Letters Ferrous Ion Chelating Modification and Treatment of Iron-Deficiency Anemia of Exopolysaccharide from Lachnum sp.
Current Chemical Biology Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Antioxidants and Free Radical Scavengers for the Treatment Of Stroke, Traumatic Brain Injury and Aging
Current Medicinal Chemistry Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Microglia-Targeted Pharmacotherapy in Retinal Neurodegenerative Diseases
Current Drug Targets Pathophysiology of Hypertension During Preeclampsia: Role of Inflammatory Cytokines
Current Hypertension Reviews VEGF, a Mediator of the Effect of Experience on Hippocampal Neurogenesis
Current Alzheimer Research Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Catalpol: A Potential Therapeutic for Neurodegenerative Diseases
Current Medicinal Chemistry Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets